SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

CX-801

CTMX·CytomX Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1
Time to market
CX-801 is in early Phase 1 dose-escalation. Even if Phase 1 completes successfully, it would need to advance through Phase 2 and potentially Phase 3 trials before any regulatory filing. Approval is likely several years away, if the program succeeds.
Why 3/10
CX-801 is an early Phase 1 asset with no hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. It is also a secondary program behind CytomX's lead asset Varseta-M (CX-2051), which is the primary value driver. The Phase 1 dose-escalation study is ongoing with no specific data-readout date announced. Per the impact score rubric, a Phase 1 drug with no imminent binary catalyst and a secondary pipeline position scores 3.
Actionable Insight NEUTRAL

CX-801 has no announced near-term catalyst. The next meaningful event for CytomX overall is the Varseta-M Phase 1 monotherapy data update in metastatic colorectal cancer expected in January 2027, which will likely drive the stock more than any CX-801 news. Watch for any CX-801 dose-escalation updates or expansion cohort announcements, but the program is early-stage and secondary to Varseta-M.

Price Chart

Loading chart...

Executive Summary

CX-801 is CytomX Therapeutics' Phase 1 conditionally activated interferon alpha-2b Probody for solid tumors, initially targeting metastatic melanoma. It uses the company's Probody platform to mask the potent interferon payload until it reaches the tumor, aiming to improve the therapeutic index. The Phase 1 dose-escalation study (NCT06462794) is evaluating CX-801 as monotherapy and in combination with Merck's KEYTRUDA. Initial biomarker data from November 2025 showed tumor-selective interferon activation. However, CX-801 is a secondary pipeline asset behind the company's lead program Varseta-M (CX-2051), and no specific near-term data readout or regulatory catalyst has been announced. The stock trades near $2.19 with a market cap around $475M and $348M cash runway into the second half of 2028.

How It Works

CX-801 is a dually-masked (conditionally activated) form of interferon alpha-2b, a protein that stimulates the immune system to fight cancer. It uses CytomX's Probody platform, which keeps the drug inactive until it reaches the tumor microenvironment, where enzymes in the tumor unmask it. This design aims to concentrate the drug's activity at the cancer site and reduce side effects compared to regular interferon therapy. CX-801 is being tested as a monotherapy and in combination with Merck's KEYTRUDA (pembrolizumab, an anti-PD-1 checkpoint inhibitor) for metastatic melanoma and other solid tumors.

Trial Status

CX-801 is in an ongoing Phase 1 dose-escalation study (NCT06462794) in patients with solid tumors, focused on metastatic melanoma. The monotherapy arm began dosing in September 2024. After clearing the first three monotherapy dose cohorts, the combination arm with KEYTRUDA (pembrolizumab) began dosing in May 2025. Initial translational biomarker data presented at the SITC annual meeting in November 2025 showed tumor-selective activation of interferon signaling and immune response in patients who had failed prior checkpoint inhibitor therapy, supporting the drug's mechanism of action. The Phase 1 study continues to enroll patients.

The Two-Sided Case

▲ Bull Case4
Initial Phase 1 biomarker data presented at SITC 2025 showed tumor-selective activation of interferon signaling, validating the Probody masking approach in patients who had failed prior checkpoint therapy.
The combination with KEYTRUDA (pembrolizumab) addresses a large market opportunity in metastatic melanoma, where interferon-based therapies could complement PD-1 inhibition.
CytomX has a strong cash runway into 2H 2028 ($348M), providing funding for CX-801 development without near-term dilution risk.
Analyst consensus is bullish: 13 of 14 analysts rate the stock Buy or Strong Buy, with a mean price target of $12.25 (roughly 421% implied upside from the current $2.19 price).
▼ Bear Case5
CX-801 is still in early Phase 1 dose-escalation with no efficacy data reported yet; the biomarker data only showed target engagement, not tumor responses.
Interferon alpha therapies have historically had significant toxicity and limited commercial success; the Probody masking may not fully overcome these challenges.
CX-801 is a secondary pipeline priority behind Varseta-M (CX-2051), which is the company's lead asset and primary value driver.
The stock has a 52-week low of $2.11 and has fallen significantly from its $8.21 high, reflecting the pre-revenue stage and execution risk across the pipeline.
Several institutional holders trimmed or exited positions in Q2 2026, including Citadel, Millennium Management, and Jefferies.

Upcoming Catalysts

  • Phase 1 dose-escalation data updates (no specific date announced)
  • Potential expansion cohort data in metastatic melanoma

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CytomX Therapeutics, Inc. 8-K CTMX ·Originating report

Sources · 8

Hover a chip for the title
1 nasdaq.com2 morningstar.com3 taiwannews.com.tw4 seekingalpha.com5 ad-hoc-news.de6 sec.gov7 seekingalpha.com8 curetoday.com